Transforming growth factor beta receptor 2 frameshift-derived peptide (TGFBR2-FSP)

Transforming growth factor beta receptor 2 (TGFBR2) frameshift-derived peptides are neoantigens produced by a recurrent -1 base pair frameshift mutation in a polyadenine (A10) tract within the TGFBR2 gene. This mutation is a hallmark of cancers characterized by microsatellite instability (MSI), such as those found in Lynch syndrome and sporadic MSI-high colorectal or gastric cancers (Saeterdal et al., 2001, PubMed: 11506501). The frameshift results in a truncated protein with a novel, highly immunogenic C-terminal amino acid sequence that is not expressed in normal human tissues. Because this specific mutation occurs frequently across different patients with MSI-H tumors, these peptides serve as ideal targets for 'off-the-shelf' cancer vaccines and T-cell therapies (Kloor & von Knebel Doeberitz, 2016, PubMed: 27049151). Therapeutic strategies involving these peptides aim to prime the host immune system to recognize and eliminate malignant cells expressing the neoantigen, thereby providing a targeted approach with minimal off-target toxicity to healthy cells.

Other names

TGFBR2 frameshift neoantigenTGFBR2(-1) frameshift peptideTGFBR2-fsTGFBR2 mutation-derived neoantigen

Induction of tumor-specific cytotoxic T-lymphocyte (CTL) response through vaccination or adoptive cell transfer targeting the neoantigen sequence.